J. Rybka, E. Stefanko, A. Bogucka-Fedorczuk, A. Butrym, R. Poręba, K. Kuliczkowski, T. Wróbel
Aim of the study Azacitidine is a hypomethylating agent which is used in the treatment of myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. Because of good tolerance to the drug, azacitidine can be administered both during hospitalization and in an outpatient setting. The aim of our retrospective analysis was to assess the efficacy of azacitidine treatment in patients with a myelodysplastic syndrome and with acute myeloid leukemia who had received treatment in hospital and in an ambulatory care setting. Offsets in the course of azacitidine administration and discontinuations of treatment have a negative impact on patients’ response to the therapy. Material and methods The study included 31 patients. Sixteen patients received azacitidine in an ambulatory care setting, 15 patients within their hospitalization. Results A hematologic response was achieved in 48% of the patients. Forty-one percent of the cycles were delayed. In an outpatient setting, 62% of the cycles were administered systematically, while during hospitalization the patients received 54% of cycles on time. Administrative problems caused the delay of 26% of the cycles. Conclusions Azacitidine has a high tolerance level and a high safety profile which allows for its use in an outpatient care setting. Outpatient administration of azacitidine is feasible and safe without compromising efficacy.
{"title":"Azacitidine in outpatient treatment – single center experience","authors":"J. Rybka, E. Stefanko, A. Bogucka-Fedorczuk, A. Butrym, R. Poręba, K. Kuliczkowski, T. Wróbel","doi":"10.5114/wo.2015.56653","DOIUrl":"https://doi.org/10.5114/wo.2015.56653","url":null,"abstract":"Aim of the study Azacitidine is a hypomethylating agent which is used in the treatment of myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. Because of good tolerance to the drug, azacitidine can be administered both during hospitalization and in an outpatient setting. The aim of our retrospective analysis was to assess the efficacy of azacitidine treatment in patients with a myelodysplastic syndrome and with acute myeloid leukemia who had received treatment in hospital and in an ambulatory care setting. Offsets in the course of azacitidine administration and discontinuations of treatment have a negative impact on patients’ response to the therapy. Material and methods The study included 31 patients. Sixteen patients received azacitidine in an ambulatory care setting, 15 patients within their hospitalization. Results A hematologic response was achieved in 48% of the patients. Forty-one percent of the cycles were delayed. In an outpatient setting, 62% of the cycles were administered systematically, while during hospitalization the patients received 54% of cycles on time. Administrative problems caused the delay of 26% of the cycles. Conclusions Azacitidine has a high tolerance level and a high safety profile which allows for its use in an outpatient care setting. Outpatient administration of azacitidine is feasible and safe without compromising efficacy.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"16 1","pages":"467 - 470"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89412599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Szajewski, W. Kruszewski, J. Lakomy, Maciej Ciesielski, K. Kawecki, J. Szefel
Aim of the study Evaluation of the relationships between increased expression of VEGF-C (vascular endothelial growth factor-C) and vessel density in the tumour-surrounding stroma, patient survival, and other conventional prognostic factors in patients with pT3-4 colon cancer. Material and methods Expression of VEGF-C and vessel density were immunohistochemically assessed in 104 specimens of primary, locally advanced (pT3-4) colon adenocarcinoma after surgical resection. Results A significant relationship was found between the expression of VEGF-C and increased vessel density in the tumour-surrounding stroma (p = 0.03). A relationship between VEGF-C expression and location of the tumour in the left side of the colon was also found (p = 0.003). Expression of VEGF-C was likely to occur in well-differentiated tumours. No relationship between patient overall survival and the expression level of VEGF-C in locally advanced colon cancer was observed. Conclusions The study results indicate that expression of VEGF-C in cells of locally advanced pT3-4 adenocarcinoma of the colon does not affect the survival time of the patients. Increased expression of VEGF-C is accompanied by a significant increase in vessel density in the pT3-4 tumour stroma. Increased expression of VEGF-C in cancer cells is related to the tumour location in the left side of the colon and better tumour differentiation.
{"title":"VEGF-C expression is not a prognostic factor in locally advanced colon adenocarcinoma","authors":"M. Szajewski, W. Kruszewski, J. Lakomy, Maciej Ciesielski, K. Kawecki, J. Szefel","doi":"10.5114/wo.2015.56649","DOIUrl":"https://doi.org/10.5114/wo.2015.56649","url":null,"abstract":"Aim of the study Evaluation of the relationships between increased expression of VEGF-C (vascular endothelial growth factor-C) and vessel density in the tumour-surrounding stroma, patient survival, and other conventional prognostic factors in patients with pT3-4 colon cancer. Material and methods Expression of VEGF-C and vessel density were immunohistochemically assessed in 104 specimens of primary, locally advanced (pT3-4) colon adenocarcinoma after surgical resection. Results A significant relationship was found between the expression of VEGF-C and increased vessel density in the tumour-surrounding stroma (p = 0.03). A relationship between VEGF-C expression and location of the tumour in the left side of the colon was also found (p = 0.003). Expression of VEGF-C was likely to occur in well-differentiated tumours. No relationship between patient overall survival and the expression level of VEGF-C in locally advanced colon cancer was observed. Conclusions The study results indicate that expression of VEGF-C in cells of locally advanced pT3-4 adenocarcinoma of the colon does not affect the survival time of the patients. Increased expression of VEGF-C is accompanied by a significant increase in vessel density in the pT3-4 tumour stroma. Increased expression of VEGF-C in cancer cells is related to the tumour location in the left side of the colon and better tumour differentiation.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"138 1","pages":"446 - 450"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80271410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz
Aim of the study To determine the cost-effectiveness of lung cancer (LC) screening with low-dose computerised tomography of the chest, as compared to an approach without screening, reimbursed today by the National Health Fund (NHF) in Poland. Material and methods In order to analyse the current costs of diagnostic and therapeutic procedures of a model LC patient treated today, a model group consisting of 199 consecutive patients diagnosed and treated in the Oncology Centre in Bydgoszcz, Poland from January 2007 to April 2010 was used. The number and type of performed procedures in this group was obtained from the Polish Register of Neoplasms and the NHF. Only direct medical costs were analysed. To calculate the total costs of screening, diagnostics, and treatment of the hypothetical LC patient who would have cancer diagnosed with screening CT, data from the literature and costs calculated for the model group were used. Prices of procedures were obtained from the price list of the NHF on 30 April 2010 and did not change from that time until June 2014. One-way sensitivity analysis was performed. Results The average cost per LC patient, diagnosed and treated without screening, is 5567.50 EUR, and median LC-specific survival is one year. In the hypothetical LC patient with cancer diagnosed by screening, the average cost is 13689.35 EUR per LC patient, with a median LC-specific survival of at least seven years. A calculated incremental cost-effectiveness ratio (ICER) is 1353.64 EUR/year of life gained. Conclusions Lung cancer screening with low-dose CT would be highly cost-effective in Poland.
{"title":"Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland","authors":"Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz","doi":"10.5114/wo.2015.56656","DOIUrl":"https://doi.org/10.5114/wo.2015.56656","url":null,"abstract":"Aim of the study To determine the cost-effectiveness of lung cancer (LC) screening with low-dose computerised tomography of the chest, as compared to an approach without screening, reimbursed today by the National Health Fund (NHF) in Poland. Material and methods In order to analyse the current costs of diagnostic and therapeutic procedures of a model LC patient treated today, a model group consisting of 199 consecutive patients diagnosed and treated in the Oncology Centre in Bydgoszcz, Poland from January 2007 to April 2010 was used. The number and type of performed procedures in this group was obtained from the Polish Register of Neoplasms and the NHF. Only direct medical costs were analysed. To calculate the total costs of screening, diagnostics, and treatment of the hypothetical LC patient who would have cancer diagnosed with screening CT, data from the literature and costs calculated for the model group were used. Prices of procedures were obtained from the price list of the NHF on 30 April 2010 and did not change from that time until June 2014. One-way sensitivity analysis was performed. Results The average cost per LC patient, diagnosed and treated without screening, is 5567.50 EUR, and median LC-specific survival is one year. In the hypothetical LC patient with cancer diagnosed by screening, the average cost is 13689.35 EUR per LC patient, with a median LC-specific survival of at least seven years. A calculated incremental cost-effectiveness ratio (ICER) is 1353.64 EUR/year of life gained. Conclusions Lung cancer screening with low-dose CT would be highly cost-effective in Poland.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"480 - 486"},"PeriodicalIF":0.0,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91008506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abiraterone is approved in combination with prednisone and a luteinizing hormone-releasing hormone (LHRH) analogue for castration-resistant prostate cancer (CPRC) patients progressing in the form of previa [1] or after treatment with docetaxel [2]. CPRC patients treated with abiraterone should take four tablets on an empty stomach one hour before breakfast, 10 mg of prednisone, and continued treatment with analogue LHRH [3]. It is an effective drug but at a cost of €36,693 per patient per year [4]. In addition, the LHRH analogue costs from €972 to €1788 per patient per year [5] (€81–€149 per month depending on the European country). Is it necessary to maintain this very expensive therapeutic scheme? Can we obtain the same results at a lower cost? Theoretically abiraterone treatment can be nearly 80% cheaper with the same therapeutic results. This can be achieved with two modifications to current treatment:
{"title":"Low cost abiraterone","authors":"Diego Barreiro, Francisco Castro","doi":"10.5114/wo.2015.56661","DOIUrl":"https://doi.org/10.5114/wo.2015.56661","url":null,"abstract":"Abiraterone is approved in combination with prednisone and a luteinizing hormone-releasing hormone (LHRH) analogue for castration-resistant prostate cancer (CPRC) patients progressing in the form of previa [1] or after treatment with docetaxel [2]. \u0000 \u0000CPRC patients treated with abiraterone should take four tablets on an empty stomach one hour before breakfast, 10 mg of prednisone, and continued treatment with analogue LHRH [3]. \u0000 \u0000It is an effective drug but at a cost of €36,693 per patient per year [4]. In addition, the LHRH analogue costs from €972 to €1788 per patient per year [5] (€81–€149 per month depending on the European country). \u0000 \u0000Is it necessary to maintain this very expensive therapeutic scheme? Can we obtain the same results at a lower cost? \u0000 \u0000Theoretically abiraterone treatment can be nearly 80% cheaper with the same therapeutic results. This can be achieved with two modifications to current treatment:","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"67 3","pages":"420 - 421"},"PeriodicalIF":0.0,"publicationDate":"2015-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91425194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim of the study To analyse the incidence of appendiceal neuroendocrine neoplasms in appendectomy specimens and establish the epidemiological and histopathological features, treatment, and clinical course. Material and methods Between 2004 and 2013, 975 patients who underwent appendectomy in Ankara Oncology Education and Research Hospital were retrospectively analysed. Results Neuroendocrine neoplasm was detected in the nine of 975 (0.9%) patients. Neuroendocrine neoplasms were diagnosed in eight patients by appendectomy, which was performed because of the prediagnosis of acute appendicitis, and in one patient by the suspicious mass detection during surgical procedures that were done in the appendix for a different reason. Eight of the patients’ tumours were in the tip of the appendix, and one of the patients’ tumours was at the base of appendix. Tumour size in 77.8% of patients was equal or less than 1 cm, in 22.2% patients it was 1–2 cm. There was tumour invasion in the muscularis propria layer in four patients, in the serosa layer in three patients, and in the deep mesoappendix in two patients. Patients were followed for a median of 78 months. In the follow-up of patients who were operated because of colon cancer, metachronous colon tumour evolved. This patient died due to progressive disease. Other patients are still disease-free. Conclusions The diagnosis of neuroendocrine neoplasm is often incidentally done after appendectomy. Tumour size is important in determining the extent of disease and in the selection of the surgical method during operation.
{"title":"Clinical experience in appendiceal neuroendocrine neoplasms","authors":"C. Ozcelik, S. Turanli, N. Bozdogan, C. Dibekoğlu","doi":"10.5114/wo.2015.56008","DOIUrl":"https://doi.org/10.5114/wo.2015.56008","url":null,"abstract":"Aim of the study To analyse the incidence of appendiceal neuroendocrine neoplasms in appendectomy specimens and establish the epidemiological and histopathological features, treatment, and clinical course. Material and methods Between 2004 and 2013, 975 patients who underwent appendectomy in Ankara Oncology Education and Research Hospital were retrospectively analysed. Results Neuroendocrine neoplasm was detected in the nine of 975 (0.9%) patients. Neuroendocrine neoplasms were diagnosed in eight patients by appendectomy, which was performed because of the prediagnosis of acute appendicitis, and in one patient by the suspicious mass detection during surgical procedures that were done in the appendix for a different reason. Eight of the patients’ tumours were in the tip of the appendix, and one of the patients’ tumours was at the base of appendix. Tumour size in 77.8% of patients was equal or less than 1 cm, in 22.2% patients it was 1–2 cm. There was tumour invasion in the muscularis propria layer in four patients, in the serosa layer in three patients, and in the deep mesoappendix in two patients. Patients were followed for a median of 78 months. In the follow-up of patients who were operated because of colon cancer, metachronous colon tumour evolved. This patient died due to progressive disease. Other patients are still disease-free. Conclusions The diagnosis of neuroendocrine neoplasm is often incidentally done after appendectomy. Tumour size is important in determining the extent of disease and in the selection of the surgical method during operation.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"10 1","pages":"410 - 413"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82368454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We read with interest the article by Savas et al. (3rd issue, vol. 19, 2015)[1] on hematogenous muscular metastasis of NSCLC in FDG-PET/CT. We would like to ask some queries. First, I would like to know about the definition of “muscle metastasis” used in the article. There might be two kinds of “muscle metastasis”: one with direct metastasis to muscle tissue, and other with muscle invasion from adjacent tissue metastasis such as bone, soft connective tissue, and skin. Did the authors included them or not? Could FDG-PET/CT differentiate them? Second, the authors described the size of muscle metastasis: 5-30 mm. How much size could detect it by FDG-PET/CT? Third, the authors described that they confirmed muscle metastasis histopahtologically in three patients. How they obtained it, biopsy or totally resection? How about the relationship with surrounding muscle, invaded or isolated? How the authors confirm it as hematogenous metastasis? Fourth, the authors followed up patients with confirmation of muscle metastasis. We would like to know whether the lesion muscle metastasis respond to chemotherapy or other therapies. If not, the lesions enlarged rapidly or not?
我们饶有兴趣地阅读了Savas et al. (3rd issue, vol. 19, 2015)[1]在FDG-PET/CT上关于NSCLC血液肌肉转移的文章。我们想问一些问题。首先，我想了解一下文章中使用的“肌肉转移”的定义。“肌肉转移”可能有两种:一种是直接转移到肌肉组织，另一种是由邻近组织转移(如骨、软结缔组织和皮肤)侵袭肌肉。作者有没有把他们包括进去?FDG-PET/CT能区分吗?其次，作者描述了肌肉转移的大小:5- 30mm。FDG-PET/CT能检测到多大尺寸?第三，作者描述了他们在三名患者中证实了肌肉转移的组织病理学。他们是怎么得到的，活组织检查还是完全切除?与周围肌肉的关系如何，侵入或孤立?作者是如何确认为血液转移的?第四，对确认有肌肉转移的患者进行随访。我们想知道病变肌肉转移是否对化疗或其他治疗有反应。如果没有，病变是否迅速扩大?
{"title":"Hematogenous muscular metastasis of NSCLC in FDG-PET/CT","authors":"H. Satoh, T. Tamura, K. Kagohashi","doi":"10.5114/wo.2015.56009","DOIUrl":"https://doi.org/10.5114/wo.2015.56009","url":null,"abstract":"We read with interest the article by Savas et al. (3rd issue, vol. 19, 2015)[1] on hematogenous muscular metastasis of NSCLC in FDG-PET/CT. We would like to ask some queries. First, I would like to know about the definition of “muscle metastasis” used in the article. There might be two kinds of “muscle metastasis”: one with direct metastasis to muscle tissue, and other with muscle invasion from adjacent tissue metastasis such as bone, soft connective tissue, and skin. Did the authors included them or not? Could FDG-PET/CT differentiate them? Second, the authors described the size of muscle metastasis: 5-30 mm. How much size could detect it by FDG-PET/CT? Third, the authors described that they confirmed muscle metastasis histopahtologically in three patients. How they obtained it, biopsy or totally resection? How about the relationship with surrounding muscle, invaded or isolated? How the authors confirm it as hematogenous metastasis? Fourth, the authors followed up patients with confirmation of muscle metastasis. We would like to know whether the lesion muscle metastasis respond to chemotherapy or other therapies. If not, the lesions enlarged rapidly or not?","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"16 36","pages":"422 - 422"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91506072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Herman, A. Komorowski, W. Wysocki, J. Tabor, R. Herman, A. Śliwczyński
Aim of the study To evaluate outcome, costs and treatment differences in rectal cancer patients between various regions in Poland. Material and methods Data from the Polish National Health Fund of all patients with rectal cancer diagnosed and treated between 2005 and 2007 were analyzed. Overall, relative 5-year survival and the percentage of patients receiving chemotherapy, radiotherapy and surgery were analyzed. The possible influence of cost of treatment per patient and mean number of rectal cancer patients per surgical oncologist were analyzed as well. Results In total 15,281 patients with rectal cancer were diagnosed and treated in Poland in 2005–2007 within the services of the National Health Fund. The overall, relative 5-year survival rate was 51.6%. Curative surgery was performed in 64.1% of patients. Radiotherapy and chemotherapy were used in 47.5% and 60.7% of patients, respectively. The mean cost of treatment of one rectal cancer patient was 32,800 PLN and there were 49.8 rectal cancer patients per specialist in surgical oncology. Important differences between regions were found in all these factors, but without a significant influence on survival. A correlation between numbers of patients per specialist in different voivodeships and survival rates was observed, as well as a correlation between percentage of surgical resection in voivodeships and survival rates (p = 0.07). Conclusions Results of treatment of colorectal cancer in Poland improved significantly during the last decade. There exist however, important disparities between regions in terms of method of treatment, costs and outcomes.
{"title":"Variation in treatment modalities, costs and outcomes of rectal cancer patients in Poland","authors":"K. Herman, A. Komorowski, W. Wysocki, J. Tabor, R. Herman, A. Śliwczyński","doi":"10.5114/wo.2015.56010","DOIUrl":"https://doi.org/10.5114/wo.2015.56010","url":null,"abstract":"Aim of the study To evaluate outcome, costs and treatment differences in rectal cancer patients between various regions in Poland. Material and methods Data from the Polish National Health Fund of all patients with rectal cancer diagnosed and treated between 2005 and 2007 were analyzed. Overall, relative 5-year survival and the percentage of patients receiving chemotherapy, radiotherapy and surgery were analyzed. The possible influence of cost of treatment per patient and mean number of rectal cancer patients per surgical oncologist were analyzed as well. Results In total 15,281 patients with rectal cancer were diagnosed and treated in Poland in 2005–2007 within the services of the National Health Fund. The overall, relative 5-year survival rate was 51.6%. Curative surgery was performed in 64.1% of patients. Radiotherapy and chemotherapy were used in 47.5% and 60.7% of patients, respectively. The mean cost of treatment of one rectal cancer patient was 32,800 PLN and there were 49.8 rectal cancer patients per specialist in surgical oncology. Important differences between regions were found in all these factors, but without a significant influence on survival. A correlation between numbers of patients per specialist in different voivodeships and survival rates was observed, as well as a correlation between percentage of surgical resection in voivodeships and survival rates (p = 0.07). Conclusions Results of treatment of colorectal cancer in Poland improved significantly during the last decade. There exist however, important disparities between regions in terms of method of treatment, costs and outcomes.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"400 - 409"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83078875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Pawełczyk, M. Marciniak, Piotr Błasiak, A. Rzechonek
Aim of the study The resection of pulmonary metastases is a routine practice of thoracic surgery wards; however, clear protocols or prognostic factors defining the surgical treatment criteria are still not available. The aim of the study is to evaluate the prognostic factors associated with long-term survival in a group of patients who underwent resection of pulmonary metastases. Material and methods A retrospective analysis was conducted on a group of 250 patients admitted to the Wrocław Thoracic Surgery Centre for radical resection of pulmonary lesions in the years 1996–2010. Results The patients included in the study (n = 250) underwent 339 thoracotomies in total. The overall five-year survival was 52.8%. The univariate data analysis showed that the survival rate was significantly better in patients subjected to more than one thoracotomy (p = 0.01674). Among the other data, such as sex, tumour histology, disease-free interval (DFI) ≤ 12 and > 12 months, DFI ≤ 36 and > 36 months, age, number of tumours identified in CT and number of tumours subject to resection, operated side, resection type, radicality of resection, extent of lymphadenectomy, and adjuvant therapy, no statistical significance was observed in univariate and multivariate analysis (p > 0.05). Conclusions Outcomes of re-metastasectomy are satisfactory if patients meet the baseline criteria for surgical treatment. None of the evaluated factors potentially influencing the patient survival was demonstrated to have any prognostic value. Further research, including the biology of tumours with pulmonary metastases, is necessary to select the group of patients that will benefit most from surgical treatment.
{"title":"Evaluation of prognostic factors in the surgical treatment of pulmonary metastases","authors":"K. Pawełczyk, M. Marciniak, Piotr Błasiak, A. Rzechonek","doi":"10.5114/wo.2015.56007","DOIUrl":"https://doi.org/10.5114/wo.2015.56007","url":null,"abstract":"Aim of the study The resection of pulmonary metastases is a routine practice of thoracic surgery wards; however, clear protocols or prognostic factors defining the surgical treatment criteria are still not available. The aim of the study is to evaluate the prognostic factors associated with long-term survival in a group of patients who underwent resection of pulmonary metastases. Material and methods A retrospective analysis was conducted on a group of 250 patients admitted to the Wrocław Thoracic Surgery Centre for radical resection of pulmonary lesions in the years 1996–2010. Results The patients included in the study (n = 250) underwent 339 thoracotomies in total. The overall five-year survival was 52.8%. The univariate data analysis showed that the survival rate was significantly better in patients subjected to more than one thoracotomy (p = 0.01674). Among the other data, such as sex, tumour histology, disease-free interval (DFI) ≤ 12 and > 12 months, DFI ≤ 36 and > 36 months, age, number of tumours identified in CT and number of tumours subject to resection, operated side, resection type, radicality of resection, extent of lymphadenectomy, and adjuvant therapy, no statistical significance was observed in univariate and multivariate analysis (p > 0.05). Conclusions Outcomes of re-metastasectomy are satisfactory if patients meet the baseline criteria for surgical treatment. None of the evaluated factors potentially influencing the patient survival was demonstrated to have any prognostic value. Further research, including the biology of tumours with pulmonary metastases, is necessary to select the group of patients that will benefit most from surgical treatment.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"2 1","pages":"378 - 384"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87401138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Somatostatin analogs (SSAs), including lanreotide, play a fundamental role in treatment of neuroendocrine tumors (NETs) of the gastrointestinal tract. SSAs control the clinical symptoms and are the treatment of choice in functioning NETs. Data indicating that SSAs have anti-proliferative activity has mainly come from prospective or retrospective observational studies. A recently published CLARINET study confirmed the anti-proliferative effect of lanreotide in a much broader range of NET patients than previously reported. As a result, it is now possible for clinicians to use lanreotide to treat patients with well-differentiated metastatic grade 1 and grade 2 GEP NETs (i.e., with a Ki-67 proliferative index < 10%) located in the pancreas, small intestine, or of unknown primary location, regardless of the degree of liver involvement. The results of the CLARINET study also challenge the current “wait and watch” strategy for NET treatment. Instead, it is proposed that SSAs are considered at an early stage of NET management, as already suggested by many organizations and scientific societies.
{"title":"Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study","authors":"B. Kos-Kudła","doi":"10.5114/wo.2015.56006","DOIUrl":"https://doi.org/10.5114/wo.2015.56006","url":null,"abstract":"Somatostatin analogs (SSAs), including lanreotide, play a fundamental role in treatment of neuroendocrine tumors (NETs) of the gastrointestinal tract. SSAs control the clinical symptoms and are the treatment of choice in functioning NETs. Data indicating that SSAs have anti-proliferative activity has mainly come from prospective or retrospective observational studies. A recently published CLARINET study confirmed the anti-proliferative effect of lanreotide in a much broader range of NET patients than previously reported. As a result, it is now possible for clinicians to use lanreotide to treat patients with well-differentiated metastatic grade 1 and grade 2 GEP NETs (i.e., with a Ki-67 proliferative index < 10%) located in the pancreas, small intestine, or of unknown primary location, regardless of the degree of liver involvement. The results of the CLARINET study also challenge the current “wait and watch” strategy for NET treatment. Instead, it is proposed that SSAs are considered at an early stage of NET management, as already suggested by many organizations and scientific societies.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"24 1","pages":"345 - 349"},"PeriodicalIF":0.0,"publicationDate":"2015-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89097748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Ezzeldin, D. El-Lebedy, A. Darwish, Ahmed El-Bastawissy, A. Shalaby
Aim of the study Complement factor H (CFH) has been known to inhibit the complement pathway and to contribute to tumour growth by suppressing the anti-tumour cell mediated response in cell lines from several malignancies. We examined the association of Try402His single nucleotide polymorphism in CFH gene with lung cancer and the interaction with cigarette smoking. Material and methods This case-control study included 80 primary lung cancer patients and 106 control subjects who were genotyped for Try402His (rs1061170) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Results Variant genotypes (Tyr/His and His/His) were overpresented among patients compared to controls (p = 0.03, OR = 2.510, 95% CI: 1.068–5.899), and the frequency of variant H allele was significantly overexpressed in cases compared to controls (p = 0.021). Tyr/His genotype was identified in 100% of small cell lung cancer (SCLC) patients vs. 34.5% of non-SCLC (NSCLC), while 20.7% of NSCLC patients were homozygous for the variant allele (His/His) (p = 0.001). Binary logistic regression analysis revealed a 2.5 times greater estimated risk for NSCLC than for SCLC among variant allele carriers, and a 7.3-fold increased risk of lung cancer among variant allele smoking carriers vs. 1.3-fold increased risk among wild allele smoking carriers. Moreover, the stage of cancer positively correlated with smoking and pack-years in allele H carriers, and the correlation was stronger among those who were homozygous for it (His/His) than those who were heterozygous (Tyr/His). Conclusions CFH 402H variant is a smoking-related risk factor for lung cancer, particularly the NSCLC.
{"title":"Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer","authors":"N. Ezzeldin, D. El-Lebedy, A. Darwish, Ahmed El-Bastawissy, A. Shalaby","doi":"10.5114/wo.2015.56202","DOIUrl":"https://doi.org/10.5114/wo.2015.56202","url":null,"abstract":"Aim of the study Complement factor H (CFH) has been known to inhibit the complement pathway and to contribute to tumour growth by suppressing the anti-tumour cell mediated response in cell lines from several malignancies. We examined the association of Try402His single nucleotide polymorphism in CFH gene with lung cancer and the interaction with cigarette smoking. Material and methods This case-control study included 80 primary lung cancer patients and 106 control subjects who were genotyped for Try402His (rs1061170) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Results Variant genotypes (Tyr/His and His/His) were overpresented among patients compared to controls (p = 0.03, OR = 2.510, 95% CI: 1.068–5.899), and the frequency of variant H allele was significantly overexpressed in cases compared to controls (p = 0.021). Tyr/His genotype was identified in 100% of small cell lung cancer (SCLC) patients vs. 34.5% of non-SCLC (NSCLC), while 20.7% of NSCLC patients were homozygous for the variant allele (His/His) (p = 0.001). Binary logistic regression analysis revealed a 2.5 times greater estimated risk for NSCLC than for SCLC among variant allele carriers, and a 7.3-fold increased risk of lung cancer among variant allele smoking carriers vs. 1.3-fold increased risk among wild allele smoking carriers. Moreover, the stage of cancer positively correlated with smoking and pack-years in allele H carriers, and the correlation was stronger among those who were homozygous for it (His/His) than those who were heterozygous (Tyr/His). Conclusions CFH 402H variant is a smoking-related risk factor for lung cancer, particularly the NSCLC.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"26 1","pages":"441 - 445"},"PeriodicalIF":0.0,"publicationDate":"2015-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84330516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：